Boiron pessimistic after a difficult first half
Boiron For the first six months of the year have been complicated. The homeopathic laboratory issued after market one dégringolage 62.4% of its net income Group share, 5.129 million euros over the period. "As announced at the publication of 2009 results, the group continued on the first half of 2010, his efforts to lay the foundations for its future development: further promotion and research, increased development investment and productivity ", justifies the group in a statement.
The half-yearly sales were flat at 221.5 million euros. A cons-performance is explained by "a context of pathology winter low.Boiron, which markets the drug against Oscillococcinum flu symptoms or treatment against cough Stodal, rose only 0.3% of its sales in France Guaranteed payday loans. Internationally, they fell by 2.7%. Operating profit fell by 55.1% to 9.186 million euros.
These results Boiron push to revise downward its objectives for the entire year. While it expects a "maintenance" of its business last March, the group now believes that "the turnover should be back from 2009. The group's profitability will depend on the level of activity of the second half and should in any event be less than 2009. "
ALSO READ:
The French supporters of self-medication